Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04026334 · ClinicalTrials.gov registry record · NA
Evaluation of V.A.C. VERAFLO CLEANSE CHOICE™ Dressing Using Normal Saline to Promote Increased Healthy Wound Bed Tissue
A NA study, sponsored by 3M.
- Terminated
- Registry status
- NA
- Development phase
- 8
- Enrollment target
NCT04026334: Clinical Trial NA study, sponsored by 3M.
NCT04026334 is a NA study that was terminated before completion, run by 3M. The registered enrollment target is 8 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04026334, a NA study, was terminated before completion, sponsored by 3M.
- TERMINATED
- Registry status
- NA
- Development phase
- 8 participants
- Enrollment target
Study Summary
The study goal is to evaluate the ability of the V.A.C. ULTA™ Negative Pressure Wound Therapy System and V.A.C. VERAFLO CLEANSE CHOICE ™ (VFCC) dressing system with saline as an irrigant in increasing viable tissue in full thickness wounds (such as chronic, acute, traumatic, sub-acute, and dehisced wounds and/or ulcers) with difficult to manage bioburden and slough.
Interventions
- DEVICE V.A.C. VERAFLO CLEANSE CHOICE™ dressing with Normal Saline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2019-07-25 |
| Est. Completion | 2020-08-28 |
| Phase | NA |
Why NCT04026334 stopped before completion
NCT04026334 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which V.A.C. VERAFLO CLEANSE CHOICE™ dressing with Normal Saline is the first listed.
NCT04026334 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04026334 about?
NCT04026334 is a clinical study titled "Evaluation of V.A.C. VERAFLO CLEANSE CHOICE™ Dressing Using Normal Saline to Promote Increased Healthy Wound Bed Tissue". The study goal is to evaluate the ability of the V.A.C. ULTA™ Negative Pressure Wound Therapy System and V.A.C. VERAFLO CLEANSE CHOICE ™ (VFCC) dressing system with saline as an irrigant in increasing viable tissue in full thickness wounds (such as chronic, acute, traumatic, sub-acute, and dehisced ...
What is the current status of trial NCT04026334?
This trial is currently terminated. It is a NA study. The enrollment target is 8 participants. The study started on 2019-07-25. Estimated completion is 2020-08-28.
What interventions are being tested in trial NCT04026334?
The interventions under investigation include: V.A.C. VERAFLO CLEANSE CHOICE™ dressing with Normal Saline (DEVICE).
Who is sponsoring clinical trial NCT04026334?
This trial is sponsored by 3M, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04026334's enrollment target sits among peer trials
8 1976th of 2000 higher than 19 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI